Macrophages in Lymphoma: Advances in Biology and Treatment

Mengya Gao; Siyue Li; Linping Xu; Shiyu Zuo; Wei Li

doi:10.53941/ti.2026.100008

Abstract

The tumor microenvironment (TME) is now recognized as a crucial factor in the development of cancer, impacting treatment strategies and resistance mechanisms. Current research indicates that the TME plays a significant role in various types of lymphoma. The diversity and prevalence of immune cells in the TME can vary greatly, and their composition and activity are believed to be key factors influencing disease progression. Emerging evidence indicates that tumor-associated macrophages (TAMs) are an important component of the TME and play a significant role in angiogenesis, extracellular matrix remodeling, tumor proliferation and metastasis, immunosuppression, resistance to chemotherapeutic agents and immune checkpoint blockade therapy. Molecules have been developed to target TAMs to treat lymphoma, and several clinical studies have investigated the safety and efficacy of targeted macrophage therapies. In this review, we summarize the roles of macrophages; elucidate distinct types of macrophage-targeted strategies that have been used to address lymphoma in preclinical experiments and clinical trials, and outline therapeutic approaches that are currently under development.

References

1.
Hinshaw, D.C.; Shevde, L.A. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019, 79, 4557–4566. https://doi.org/10.1158/0008-5472.CAN-18-3962.
2.
Binnewies, M.; Roberts, E.W.; Kersten, K.; et al. Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nat. Med. 2018, 24, 541–550. https://doi.org/10.1038/s41591-018-0014-x.
3.
Mantovani, A.; Allavena, P.; Marchesi, F.; et al. Macrophages as Tools and Targets in Cancer Therapy. Nat. Rev. Drug Discov. 2022, 21, 799–820. https://doi.org/10.1038/s41573-022-00520-5.
4.
Sica, A.; Larghi, P.; Mancino, A.; et al. Macrophage Polarization in Tumour Progression. Semin. Cancer Biol. 2008, 18, 349–355. https://doi.org/10.1016/j.semcancer.2008.03.004.
5.
Zhang, W.; Wang, M.; Ji, C.; et al. Macrophage Polarization in the Tumor Microenvironment: Emerging Roles and Therapeutic Potentials. Biomed. Pharmacother. 2024, 177, 116930. https://doi.org/10.1016/j.biopha.2024.116930.
6.
Locati, M.; Curtale, G.; Mantovani, A. Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu. Rev. Pathol. 2020, 15, 123–147. https://doi.org/10.1146/annurev-pathmechdis-012418-012718.
7.
Wagle, N.S.; Nogueira, L.; Devasia, T.P.; et al. Cancer Treatment and Survivorship Statistics, 2025. CA Cancer J. Clin. 2025, 75, 308–340. https://doi.org/10.3322/caac.70011.
8.
Armitage, J.O.; Gascoyne, R.D.; Lunning, M.A.; et al. Non-Hodgkin Lymphoma. Lancet 2017, 390, 298–310. https://doi.org/10.1016/S0140-6736(16)32407-2.
9.
Tang, W.; Wang, X.; Han, B.; et al. Tumor-Associated Macrophages in Cancer: From Mechanisms to Application. Mol. Biomed. 2025, 6, 145. https://doi.org/10.1186/s43556-025-00396-y.
10.
Cao, L.; Meng, X.; Zhang, Z.; et al. Macrophage Heterogeneity and Its Interactions with Stromal Cells in Tumour Microenvironment. Cell Biosci. 2024, 14, 16. https://doi.org/10.1186/s13578-024-01201-z.
11.
Guo, S.; Chen, X.; Guo, C.; et al. Tumour-Associated Macrophages Heterogeneity Drives Resistance to Clinical Therapy. Expert. Rev. Mol. Med. 2022, 24, e17. https://doi.org/10.1017/erm.2022.8.
12.
Lin, M.; Ma, S.; Sun, L.; et al. The Prognostic Value of Tumor-Associated Macrophages Detected by Immunostaining in Diffuse Large B Cell Lymphoma: A Meta-Analysis. Front. Oncol. 2022, 12, 1094400. https://doi.org/10.3389/fonc.2022.1094400.
13.
Wei, X.; Yang, S.; Pu, X.; et al. Tumor-Associated Macrophages Increase the Proportion of Cancer Stem Cells in Lymphoma by Secreting Pleiotrophin. Am. J. Transl. Res. 2019, 11, 6393–6402.
14.
Nam, S.J.; Kim, S.; Kwon, D.; et al. Prognostic Implications of Tumor-Infiltrating Macrophages, M2 Macrophages, Regulatory T-Cells, and Indoleamine 2,3-Dioxygenase-Positive Cells in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. Oncoimmunology 2018, 7, e1442164. https://doi.org/10.1080/2162402X.2018.1442164.
15.
Steidl, C.; Lee, T.; Shah, S.P.; et al. Tumor-Associated Macrophages and Survival in Classic Hodgkin’s Lymphoma. N. Engl. J. Med. 2010, 362, 875–885. https://doi.org/10.1056/NEJMoa0905680.
16.
Le, K.; Sun, J.; Khawaja, H.; et al. Mantle Cell Lymphoma Polarizes Tumor-Associated Macrophages into M2-like Macrophages, Which in Turn Promote Tumorigenesis. Blood Adv. 2021, 5, 2863–2878. https://doi.org/10.1182/bloodadvances.2020003871.
17.
Taskinen, M.; Karjalainen-Lindsberg, M.-L.; Nyman, H.; et al. A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone. Clin. Cancer Res. 2007, 13, 5784–5789. https://doi.org/10.1158/1078-0432.CCR-07-0778.
18.
Ribatti, D.; Tamma, R.; Annese, T.; et al. Macrophages and Angiogenesis in Human Lymphomas. Clin. Exp. Med. 2024, 24, 26. https://doi.org/10.1007/s10238-023-01291-y.
19.
Riabov, V.; Gudima, A.; Wang, N.; et al. Role of Tumor Associated Macrophages in Tumor Angiogenesis and Lymphangiogenesis. Front. Physiol. 2014, 5, 75. https://doi.org/10.3389/fphys.2014.00075.
20.
Werner, L.; Dreyer, J.H.; Hartmann, D.; et al. Tumor-Associated Macrophages in Classical Hodgkin Lymphoma: Hormetic Relationship to Outcome. Sci. Rep. 2020, 10, 9410. https://doi.org/10.1038/s41598-020-66010-z.
21.
Panico, L.; Ronconi, F.; Lepore, M.; et al. Prognostic Role of Tumor-Associated Macrophages and Angiogenesis in Classical Hodgkin Lymphoma. Leuk. Lymphoma 2013, 54, 2418–2425. https://doi.org/10.3109/10428194.2013.778405.
22.
Zhang, W.; Wang, L.; Zhou, D.; et al. Expression of Tumor-Associated Macrophages and Vascular Endothelial Growth Factor Correlates with Poor Prognosis of Peripheral T-Cell Lymphoma, Not Otherwise Specified. Leuk. Lymphoma 2011, 52, 46–52. https://doi.org/10.3109/10428194.2010.529204.
23.
Manfroi, B.; De Grandis, M.; Moreaux, J.; et al. The Microenvironment of DLBCL Is Characterized by Noncanonical Macrophages Recruited by Tumor-Derived CCL5. Blood Adv. 2021, 5, 4338–4351. https://doi.org/10.1182/bloodadvances.2021004203.
24.
Xie, Y.; Yang, H.; Yang, C.; et al. Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies. Front. Oncol. 2022, 12, 933666. https://doi.org/10.3389/fonc.2022.933666.
25.
Friedman-DeLuca, M.; Karagiannis, G.S.; Condeelis, J.S.; et al. Macrophages in Tumor Cell Migration and Metastasis. Front. Immunol. 2024, 15, 1494462. https://doi.org/10.3389/fimmu.2024.1494462.
26.
Mantovani, A.; Marchesi, F.; Di Mitri, D.; et al. Macrophage Diversity in Cancer Dissemination and Metastasis. Cell Mol. Immunol. 2024, 21, 1201–1214. https://doi.org/10.1038/s41423-024-01216-z.
27.
Ohe, R. Mechanisms of Lymphoma-Stromal Interactions Focusing on Tumor-Associated Macrophages, Fibroblastic Reticular Cells, and Follicular Dendritic Cells. J. Clin. Exp. Hematop. 2024, 64, 166–176. https://doi.org/10.3960/jslrt.24034.
28.
Andersen, M.D.; Wolter, K.; Enemark, M.H.; et al. Tumor-Associated Macrophages: Potential Role in Skeletal Involvement in Classic Hodgkin Lymphoma. J. Pathol. Clin. Res. 2025, 11, e70038. https://doi.org/10.1002/2056-4538.70038.
29.
Xiong, X.; Xie, X.; Wang, Z.; et al. Tumor-Associated Macrophages in Lymphoma: From Mechanisms to Therapy. Int. Immunopharmacol. 2022, 112, 109235. https://doi.org/10.1016/j.intimp.2022.109235.
30.
Gordon, S.R.; Maute, R.L.; Dulken, B.W.; et al. PD-1 Expression by Tumour-Associated Macrophages Inhibits Phagocytosis and Tumour Immunity. Nature 2017, 545, 495–499. https://doi.org/10.1038/nature22396.
31.
Jiang, X.-H.; Chen, Y.-J. [The Role of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Lymphoma--Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2025, 33, 1217–1221. https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.04.043.
32.
Roemer, M.G.M.; Advani, R.H.; Ligon, A.H.; et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J. Clin. Oncol. 2016, 34, 2690–2697. https://doi.org/10.1200/JCO.2016.66.4482.
33.
Galtier, J.; Peanne, R.; Le Morvan, V.; et al. Cutaneous Diffuse Large B-Cell Lymphoma Induces a Macrophage Immunosuppressive Phenotype through IL-10 Secretion. Blood Adv. 2026, 10, 850–863. https://doi.org/10.1182/bloodadvances.2025016492.
34.
Huang, W.; Wei, X.; Wei, Y.; et al. Biology of Tumor Associated Macrophages in Diffuse Large B Cell Lymphoma. DNA Cell Biol. 2018, 37, 947–952. https://doi.org/10.1089/dna.2018.4374.
35.
de Matos Rodrigues, J.; Lokhande, L.; Olsson, L.M.; et al. CD163+ Macrophages in Mantle Cell Lymphoma Induce Activation of Prosurvival Pathways and Immune Suppression. Blood Adv. 2024, 8, 4370–4385. https://doi.org/10.1182/bloodadvances.2023012039.
36.
Han, Z.; Wu, X.; Qin, H.; et al. Reprogramming of PD-1+ M2-like Tumor-Associated Macrophages with Anti-PD-L1 and Lenalidomide in Cutaneous T Cell Lymphoma. JCI Insight 2023, 8, e163518. https://doi.org/10.1172/jci.insight.163518.
37.
Yang, Y.; Li, S.; To, K.K.W.; et al. Tumor-Associated Macrophages Remodel the Suppressive Tumor Immune Microenvironment and Targeted Therapy for Immunotherapy. J. Exp. Clin. Cancer Res. 2025, 44, 145. https://doi.org/10.1186/s13046-025-03377-9.
38.
Zhang, C.; Wang, L.; Xu, C.; et al. Resistance Mechanisms of Immune Checkpoint Inhibition in Lymphoma: Focusing on the Tumor Microenvironment. Front. Pharmacol. 2023, 14. https://doi.org/10.3389/fphar.2023.1079924.
39.
Garcia-Lacarte, M.; Grijalba, S.C.; Melchor, J.; et al. IL-10 from Tumoral B Cells Modulates the Diffuse Large B-Cell Lymphoma Microenvironment and Response to Immunotherapy. Blood 2025, 145, 2746–2761. https://doi.org/10.1182/blood.2024025755.
40.
Sasayama, T.; Tanaka, K.; Mizowaki, T.; et al. Tumor-Associated Macrophages Associate with Cerebrospinal Fluid Interleukin-10 and Survival in Primary Central Nervous System Lymphoma (PCNSL). Brain Pathol. 2016, 26, 479–487. https://doi.org/10.1111/bpa.12318.
41.
Zhao, P.; Xie, L.; Yu, L.; et al. Targeting CD47-SIRPα Axis for Hodgkin and Non-Hodgkin Lymphoma Immunotherapy. Genes. Dis. 2024, 11, 205–217. https://doi.org/10.1016/j.gendis.2022.12.008.
42.
Maute, R.; Xu, J.; Weissman, I.L. CD47–SIRPα-Targeted Therapeutics: Status and Prospects. Immunooncol Technol. 2022, 13, 100070. https://doi.org/10.1016/j.iotech.2022.100070.
43.
Yang, H.; Xun, Y.; You, H. The Landscape Overview of CD47-Based Immunotherapy for Hematological Malignancies. Biomark. Res. 2023, 11, 15. https://doi.org/10.1186/s40364-023-00456-x.
44.
Biedermann, A.; Patra-Kneuer, M.; Mougiakakos, D.; et al. Blockade of the CD47/SIRPα Checkpoint Axis Potentiates the Macrophage-Mediated Antitumor Efficacy of Tafasitamab. Haematologica 2024, 109, 3928–3940. https://doi.org/10.3324/haematol.2023.284795.
45.
Lakhotia, R.; Melani, C.; Pittaluga, S.; et al. The Anti-CD47 Antibody Magrolimab with Obinutuzumab and Venetoclax in Relapsed or Refractory Indolent B-Cell Lymphomas. Br. J. Haematol. 2025, 207, 612–618. https://doi.org/10.1111/bjh.20219.
46.
Guo, X.; Fu, Y.; Baran, N.; et al. CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge. OR 2025, 33, 3375–3385. https://doi.org/10.32604/or.2025.071708.
47.
Chen, Q.; Guo, X.; Ma, W. Opportunities and Challenges of CD47-Targeted Therapy in Cancer Immunotherapy. OR 2023, 32, 49–60. https://doi.org/10.32604/or.2023.042383.
48.
Mirza, W.; Dadan, S.; Ahmad, E.; et al. Clinical Outcomes and Safety of CD47-Targeted Immunotherapies across Hematologic Malignancies: A Systematic Review of Monoclonal Antibodies and Fusion Proteins in Combination Strategies. Clin. Exp. Med. 2025, 25, 360. https://doi.org/10.1007/s10238-025-01915-5.
49.
Zhang, B.; Li, W.; Fan, D.; et al. Advances in the Study of CD47-Based Bispecific Antibody in Cancer Immunotherapy. Immunology 2022, 167, 15–27. https://doi.org/10.1111/imm.13498.
50.
Bouwstra, R.; van Meerten, T.; Bremer, E. CD47-SIRPα Blocking-Based Immunotherapy: Current and Prospective Therapeutic Strategies. Clin. Transl. Med. 2022, 12, e943. https://doi.org/10.1002/ctm2.943.
51.
Chao, M.P.; Alizadeh, A.A.; Tang, C.; et al. Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. Cancer Res. 2011, 71, 1374–1384. https://doi.org/10.1158/0008-5472.CAN-10-2238.
52.
Liu, X.; Pu, Y.; Cron, K.; et al. CD47 Blockade Triggers T Cell-Mediated Destruction of Immunogenic Tumors. Nat. Med. 2015, 21, 1209–1215. https://doi.org/10.1038/nm.3931.
53.
Piccione, E.C.; Juarez, S.; Liu, J.; et al. A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing Lymphoma Cells. MAbs 2015, 7, 946–956. https://doi.org/10.1080/19420862.2015.1062192.
54.
Weiskopf, K.; Ring, A.M.; Ho, C.C.M.; et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science 2013, 341, 88–91. https://doi.org/10.1126/science.1238856.
55.
Advani, R.; Flinn, I.; Popplewell, L.; et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. N. Engl. J. Med. 2018, 379, 1711–1721. https://doi.org/10.1056/NEJMoa1807315.
56.
Barkal, A.A.; Weiskopf, K.; Kao, K.S.; et al. Engagement of MHC Class I by the Inhibitory Receptor LILRB1 Suppresses Macrophages and Is a Target of Cancer Immunotherapy. Nat. Immunol. 2018, 19, 76–84. https://doi.org/10.1038/s41590-017-0004-z.
57.
Hodges, A.; Dubuque, R.; Chen, S.-H.; et al. The LILRB Family in Hematologic Malignancies: Prognostic Associations, Mechanistic Considerations, and Therapeutic Implications. Biomark. Res. 2024, 12, 159. https://doi.org/10.1186/s40364-024-00705-7.
58.
Zeller, T.; Lutz, S.; Münnich, I.A.; et al. Dual Checkpoint Blockade of CD47 and LILRB1 Enhances CD20 Antibody-Dependent Phagocytosis of Lymphoma Cells by Macrophages. Front. Immunol. 2022, 13, 929339. https://doi.org/10.3389/fimmu.2022.929339.
59.
Hu, Z.; Zhang, Q.; He, Z.; et al. MHC1/LILRB1 Axis as an Innate Immune Checkpoint for Cancer Therapy. Front. Immunol. 2024, 15, 1421092. https://doi.org/10.3389/fimmu.2024.1421092.
60.
Wang, X.-Y.; Facciponte, J.; Chen, X.; et al. Scavenger Receptor-A Negatively Regulates Antitumor Immunity. Cancer Res. 2007, 67, 4996–5002. https://doi.org/10.1158/0008-5472.CAN-06-3138.
61.
Georgoudaki, A.-M.; Prokopec, K.E.; Boura, V.F.; et al. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep. 2016, 15, 2000–2011. https://doi.org/10.1016/j.celrep.2016.04.084.
62.
Nguyen, T.T.; Schwartz, E.J.; West, R.B.; et al. Expression of CD163 (Hemoglobin Scavenger Receptor) in Normal Tissues, Lymphomas, Carcinomas, and Sarcomas Is Largely Restricted to the Monocyte/Macrophage Lineage. Am. J. Surg. Pathol. 2005, 29, 617–624. https://doi.org/10.1097/01.pas.0000157940.80538.ec.
63.
Post, G.R.; Yuan, Y.; Holthoff, E.R.; et al. Identification of a Novel Monocytic Phenotype in Classic Hodgkin Lymphoma Tumor Microenvironment. PLoS ONE 2019, 14, e0224621. https://doi.org/10.1371/journal.pone.0224621.
64.
Kridel, R.; Xerri, L.; Gelas-Dore, B.; et al. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. Clin. Cancer Res. 2015, 21, 3428–3435. https://doi.org/10.1158/1078-0432.CCR-14-3253.
65.
Ruan, J.; Ouyang, M.; Zhang, W.; et al. The Effect of PD-1 Expression on Tumor-Associated Macrophage in T Cell Lymphoma. Clin. Transl. Oncol. 2021, 23, 1134–1141. https://doi.org/10.1007/s12094-020-02499-0.
66.
McCord, R.; Bolen, C.R.; Koeppen, H.; et al. PD-L1 and Tumor-Associated Macrophages in de Novo DLBCL. Blood Adv. 2019, 3, 531–540. https://doi.org/10.1182/bloodadvances.2018020602.
67.
Pollari, M.; Brück, O.; Pellinen, T.; et al. PD-L1+ Tumor-Associated Macrophages and PD-1+ Tumor-Infiltrating Lymphocytes Predict Survival in Primary Testicular Lymphoma. Haematologica 2018, 103, 1908–1914. https://doi.org/10.3324/haematol.2018.197194.
68.
Vonderheide, R.H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu. Rev. Med. 2020, 71, 47–58. https://doi.org/10.1146/annurev-med-062518-045435.
69.
Byrne, K.T.; Vonderheide, R.H. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016, 15, 2719–2732. https://doi.org/10.1016/j.celrep.2016.05.058.
70.
Wu, Z.; Yang, Z.; Iftikhar, T.; et al. CD40 Agonist Improves the Therapeutic Efficacy of Irreversible Electroporation Ablation for Metastatic Melanoma by Promoting Unexpected CD8+CD103+ cDC1 and TRM Cell Responses. Cancer Immunol. Immunother. 2025, 74, 378. https://doi.org/10.1007/s00262-025-04217-7.
71.
Luheshi, N.; Davies, G.; Legg, J. Understanding the Influence of the Tumor Microenvironment on Macrophage Responses to CD40 Agonists. Oncoimmunology 2014, 3, e27615. https://doi.org/10.4161/onci.27615.
72.
Filip, D.; Litzmanova, K.; Michaelou, A.; et al. Repression of miR-29 via MYC Leads to Increased CD40 Signaling in Transformed Follicular Lymphoma. Leukemia 2026, 40, 759–772. https://doi.org/10.1038/s41375-026-02868-8.
73.
Kobayashi, C.; Suzuki-Imaizumi, M.; Sakaguchi, Y.; et al. The Novel and Potent CD40 Agonist KHK2840 Augments the Antitumor Efficacy of Anti-PD-1 Antibody and Paclitaxel. Cancer Sci. 2024, 115, 4008–4020. https://doi.org/10.1111/cas.16366.
74.
Javaid, N.; Choi, S. Toll-like Receptors from the Perspective of Cancer Treatment. Cancers 2020, 12, 297. https://doi.org/10.3390/cancers12020297.
75.
Wang, L.; Li, Y.; He, Z.; et al. Therapeutic Targeting of Toll-like Receptor Pathways in Tumor-Associated Macrophages. Cytokine Growth Factor. Rev. 2026, 88, 138–151. https://doi.org/10.1016/j.cytogfr.2026.02.001.
76.
Wang, X.; Li, X.; Zhang, X.; et al. Toll-like Receptor 4-Induced Inflammatory Responses Contribute to the Tumor-Associated Macrophages Formation and Infiltration in Patients with Diffuse Large B-Cell Lymphoma. Ann. Diagn. Pathol. 2015, 19, 232–238. https://doi.org/10.1016/j.anndiagpath.2015.04.008.
77.
Randall, M.P.; Geng, H.; Chen, L.; et al. Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Blood 2024, 144, 978. https://doi.org/10.1182/blood-2024-212194.
78.
Yang, Y.; Li, H.; Fotopoulou, C.; et al. Toll-like Receptor-Targeted Anti-Tumor Therapies: Advances and Challenges. Front. Immunol. 2022, 13, 1049340. https://doi.org/10.3389/fimmu.2022.1049340.
79.
Dang, B.-T.N.; Duwa, R.; Lee, S.; et al. Targeting Tumor-Associated Macrophages with Mannosylated Nanotherapeutics Delivering TLR7/8 Agonist Enhances Cancer Immunotherapy. J. Control Release 2024, 372, 587–608. https://doi.org/10.1016/j.jconrel.2024.06.062.
80.
Shen, M.; Jiang, X.; Peng, Q.; et al. The cGAS‒STING Pathway in Cancer Immunity: Mechanisms, Challenges, and Therapeutic Implications. J. Hematol. Oncol. 2025, 18, 40. https://doi.org/10.1186/s13045-025-01691-5.
81.
Zhang, J.; Yu, S.; Peng, Q.; et al. Emerging Mechanisms and Implications of cGAS-STING Signaling in Cancer Immunotherapy Strategies. Cancer Biol. Med. 2024, 21, 45–64. https://doi.org/10.20892/j.issn.2095-3941.2023.0440.
82.
Nicolai, C.J.; Wolf, N.; Chang, I.-C.; et al. NK Cells Mediate Clearance of CD8+ T Cell-Resistant Tumors in Response to STING Agonists. Sci. Immunol. 2020, 5, eaaz2738. https://doi.org/10.1126/sciimmunol.aaz2738.
83.
Gusliakova, O.I.; Mikhailova, L.V.; Inozemtseva, O.A.; et al. Light-Directed Reprogramming of Tumor-Associated Macrophages via STING Agonist Delivery. Biomater. Adv. 2026, 181, 214632. https://doi.org/10.1016/j.bioadv.2025.214632.
84.
Cai, Y.; Chen, X.; Lu, T.; et al. Activation of STING by SAMHD1 Deficiency Promotes PANoptosis and Enhances Efficacy of PD-L1 Blockade in Diffuse Large B-Cell Lymphoma. Int. J. Biol. Sci. 2023, 19, 4627–4643. https://doi.org/10.7150/ijbs.85236.
85.
Xing, Y.; Peng, A.; Yang, J.; et al. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy. Adv. Sci. 2024, 11, e2309583. https://doi.org/10.1002/advs.202309583.
86.
Dahal, L.N.; Dou, L.; Hussain, K.; et al. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Res. 2017, 77, 3619–3631. https://doi.org/10.1158/0008-5472.CAN-16-2784.
87.
Lu, X.; Wang, S.; Hua, X.; et al. Targeting the cGAS-STING Pathway Inhibits Peripheral T-Cell Lymphoma Progression and Enhances the Chemotherapeutic Efficacy. Adv. Sci. 2024, 11, e2306092. https://doi.org/10.1002/advs.202306092.
88.
Yue, B.; Gao, W.; Lovell, J.F.; et al. The cGAS-STING Pathway in Cancer Immunity: Dual Roles, Therapeutic Strategies, and Clinical Challenges. Essays Biochem. 2025, 69, EBC20253006. https://doi.org/10.1042/EBC20253006.
89.
Khantakova, D.; Brioschi, S.; Molgora, M. Exploring the Impact of TREM2 in Tumor-Associated Macrophages. Vaccines 2022, 10, 943. https://doi.org/10.3390/vaccines10060943.
90.
Park, M.D.; Reyes-Torres, I.; LeBerichel, J.; et al. TREM2 Macrophages Drive NK Cell Paucity and Dysfunction in Lung Cancer. Nat. Immunol. 2023, 24, 792–801. https://doi.org/10.1038/s41590-023-01475-4.
91.
Molgora, M.; Esaulova, E.; Vermi, W.; et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 2020, 182, 886–900.e17. https://doi.org/10.1016/j.cell.2020.07.013.
92.
Li, W.; Wang, F.; Guo, R.; et al. Targeting Macrophages in Hematological Malignancies: Recent Advances and Future Directions. J. Hematol. Oncol. 2022, 15, 110. https://doi.org/10.1186/s13045-022-01328-x.
93.
Murga-Zamalloa, C.; Rolland, D.C.M.; Polk, A.; et al. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability. Clin. Cancer Res. 2020, 26, 690–703. https://doi.org/10.1158/1078-0432.CCR-19-1486.
94.
Gao, X.; Kady, N.; Wang, C.; et al. Targeting Lymphoma-Associated Macrophage Expansion via CSF1R/JAK Inhibition Is a Therapeutic Vulnerability in Peripheral T-Cell Lymphomas. Cancer Res. Commun. 2022, 2, 1727–1737. https://doi.org/10.1158/2767-9764.CRC-22-0336.
95.
Valero, J.G.; Matas-Céspedes, A.; Arenas, F.; et al. The Receptor of the Colony-Stimulating Factor-1 (CSF-1R) Is a Novel Prognostic Factor and Therapeutic Target in Follicular Lymphoma. Leukemia 2021, 35, 2635–2649. https://doi.org/10.1038/s41375-021-01201-9.
96.
Wen, Z.-F.; Huang, Q.-T.; Wang, Y.-Y.; et al. MCP-1-CCR2-M2 Macrophages Axis Contributes to Diffuse Large B-Cell Lymphoma Progression and Inhibits Antitumor Immune Response. Sci. Rep. 2025, 15, 29044. https://doi.org/10.1038/s41598-025-14527-6.
97.
Le, K.; Sun, J.; Ghaemmaghami, J.; et al. Blockade of CCR1 Induces a Phenotypic Shift in Macrophages and Triggers a Favorable Antilymphoma Activity. Blood Adv. 2023, 7, 3952–3967. https://doi.org/10.1182/bloodadvances.2022008722.
98.
Chen, Y.; Liu, Y.; Han, L. Spatial Landscape of the Tumor Immune Microenvironment. Trends in Cancer 2023, 9, 459–460. https://doi.org/10.1016/j.trecan.2023.03.006.
99.
Stahl, D.; Gödel, P.; Balke-Want, H.; et al. CSF1R+ Myeloid-Monocytic Cells Drive CAR-T Cell Resistance in Aggressive B Cell Lymphoma. Cancer Cell 2025, 43, 1476–1494.e10. https://doi.org/10.1016/j.ccell.2025.05.013.
100.
Klichinsky, M.; Ruella, M.; Shestova, O.; et al. Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nat. Biotechnol. 2020, 38, 947–953. https://doi.org/10.1038/s41587-020-0462-y.
101.
Yang, S.; Wang, Y.; Jia, J.; et al. Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy. Cell Death Dis. 2024, 15, 238. https://doi.org/10.1038/s41419-024-06616-7.
102.
Shi, Y.; Li, X.; Dong, Y.; et al. Exploring the Potential of CAR-Macrophage Therapy. Life Sci. 2025, 361, 123300. https://doi.org/10.1016/j.lfs.2024.123300.
103.
Wang, S.; Yang, Y.; Ma, P.; et al. CAR-Macrophage: An Extensive Immune Enhancer to Fight Cancer. eBioMedicine 2022, 76, 103873. https://doi.org/10.1016/j.ebiom.2022.103873.
104.
Jing, J.; Chen, Y.; Chi, E.; et al. New Power in Cancer Immunotherapy: The Rise of Chimeric Antigen Receptor Macrophage (CAR-M). J. Transl. Med. 2025, 23, 1182. https://doi.org/10.1186/s12967-025-07115-9.
105.
Ball, M.; Kremp, M.; Qureshi, R.; et al. 315 Characterization of CT-0508, an Anti-HER2 Chimeric Antigen Receptor Macrophage (CAR-M), Manufactured from Patients Enrolled in the Phase 1, First in Human, Clinical Trial of CT-0508. J. Immunother. Cancer 2022, 10, 315. https://doi.org/10.1136/jitc-2022-SITC2022.0315.
106.
Reiss, K.A.; Angelos, M.G.; Dees, E.C.; et al. CAR-Macrophage Therapy for HER2-Overexpressing Advanced Solid Tumors: A Phase 1 Trial. Nat. Med. 2025, 31, 1171–1182. https://doi.org/10.1038/s41591-025-03495-z.
107.
Block, A.; Liu, X.; Zhang, D.; et al. Engineering Macrophages for Cancer Immunotherapy: Emerging Insights and Therapeutic Potential. NPJ Biomed. Innov. 2026, 3, 18. https://doi.org/10.1038/s44385-026-00072-y.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us